About Potassium channel subfamily K member 2
Potassium channel subfamily K member 2 (KCNK2) is a protein
from Homo sapiens identified by UniProt accession
O95069, 426 residues long.
MolForge cross-references it against 0 known binders and
197 disease associations.
Target properties
| Protein name | Potassium channel subfamily K member 2 |
| UniProt accession | O95069 |
| Gene | KCNK2 |
| Organism | Homo sapiens |
| Length | 426 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (197)
Diseases linked to this target (Open Targets).
- delirium · score 0.56
- Agitation · score 0.55
- coronary artery disease · score 0.55
- pain · score 0.54
- ischemia reperfusion injury · score 0.54
- kidney failure · score 0.53
- acute respiratory distress syndrome · score 0.52
- hypotension · score 0.50
- post operative nausea and vomiting · score 0.50
- COVID-19 · score 0.48
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O95069-F1 | alphafold | PREDICTED | 76.10 | — |
Amino-acid sequence (426 residues)
MLPSASRERP GYRAGVAAPD LLDPKSAAQN SKPRLSFSTK PTVLASRVES DTTINVMKWK TVSTIFLVVV LYLIIGATVF KALEQPHEIS QRTTIVIQKQ TFISQHSCVN STELDELIQQ IVAAINAGII PLGNTSNQIS HWDLGSSFFF AGTVITTIGF GNISPRTEGG KIFCIIYALL GIPLFGFLLA GVGDQLGTIF GKGIAKVEDT FIKWNVSQTK IRIISTIIFI LFGCVLFVAL PAIIFKHIEG WSALDAIYFV VITLTTIGFG DYVAGGSDIE YLDFYKPVVW FWILVGLAYF AAVLSMIGDW LRVISKKTKE EVGEFRAHAA EWTANVTAEF KETRRRLSVE IYDKFQRATS IKRKLSAELA GNHNQELTPC RRTLSVNHLT SERDVLPPLL KTESIYLNGL TPHCAGEEIA VIENIK
Explore Potassium channel subfamily K member 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets